Head to Head Analysis: LogicMark (OTCMKTS:LGMKD) & Treace Medical Concepts (NASDAQ:TMCI)

LogicMark (OTCMKTS:LGMKD) and Treace Medical Concepts (NASDAQ:TMCI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for LogicMark and Treace Medical Concepts, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LogicMark	0	1	0	0	2.00
Treace Medical Concepts	2	4	1	0	1.86

Treace Medical Concepts has a consensus target price of $5.17, suggesting a potential upside of 11.66%. Given Treace Medical Concepts’ higher probable upside, analysts clearly believe Treace Medical Concepts is more favorable than LogicMark.

Volatility & Risk

LogicMark has a beta of 1.67, suggesting that its share price is 67% more volatile than the S&P 500. Comparatively, Treace Medical Concepts has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500.

Valuation & Earnings

This table compares LogicMark and Treace Medical Concepts”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LogicMark	$9.90 million	0.11	-$9.00 million	($94.52)	-0.01
Treace Medical Concepts	$212.69 million	1.42	-$59.00 million	($0.93)	-4.98

LogicMark has higher earnings, but lower revenue than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than LogicMark, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares LogicMark and Treace Medical Concepts’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LogicMark	-90.21%	-57.08%	-44.90%
Treace Medical Concepts	-28.99%	-71.37%	-30.49%

Institutional & Insider Ownership

7.9% of LogicMark shares are held by institutional investors. Comparatively, 84.1% of Treace Medical Concepts shares are held by institutional investors. 2.2% of LogicMark shares are held by insiders. Comparatively, 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Treace Medical Concepts beats LogicMark on 9 of the 14 factors compared between the two stocks.

About LogicMark

LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company’s devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one’s health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.

About Treace Medical Concepts

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.